- Home
- TAK vs EW Comparison
TAK vs EW Comparison
Compare TAK & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- EW
- Stock Information
- Founded
- TAK 1781
- EW 1958
- Country
- TAK Japan
- EW United States
- Employees
- TAK N/A
- EW N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- EW Industrial Specialties
- Sector
- TAK Health Care
- EW Health Care
- Exchange
- TAK Nasdaq
- EW Nasdaq
- Market Cap
- TAK 42.2B
- EW 42.1B
- IPO Year
- TAK N/A
- EW 2000
- Fundamental
- Price
- TAK $14.90
- EW $71.89
- Analyst Decision
- TAK
- EW Buy
- Analyst Count
- TAK 0
- EW 21
- Target Price
- TAK N/A
- EW $79.95
- AVG Volume (30 Days)
- TAK 1.5M
- EW 4.6M
- Earning Date
- TAK 05-08-2025
- EW 04-24-2025
- Dividend Yield
- TAK 3.95%
- EW N/A
- EPS Growth
- TAK 15.39
- EW 202.39
- EPS
- TAK 0.83
- EW 6.97
- Revenue
- TAK $29,124,927,177.00
- EW $5,439,500,000.00
- Revenue This Year
- TAK $8.53
- EW $10.16
- Revenue Next Year
- TAK N/A
- EW $9.73
- P/E Ratio
- TAK $34.90
- EW $10.32
- Revenue Growth
- TAK 9.83
- EW 8.57
- 52 Week Low
- TAK $12.58
- EW $58.93
- 52 Week High
- TAK $15.31
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- TAK 54.70
- EW 54.17
- Support Level
- TAK $14.75
- EW $70.33
- Resistance Level
- TAK $15.17
- EW $72.74
- Average True Range (ATR)
- TAK 0.17
- EW 1.50
- MACD
- TAK -0.08
- EW 0.27
- Stochastic Oscillator
- TAK 26.79
- EW 84.32
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.